Patents by Inventor Rongrong PU

Rongrong PU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered immune cell and use thereof
    Patent number: 11896620
    Abstract: An engineered immune cell, which expresses (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and/or XCL1; the engineered immune cell can be used for treating cancer, infection, or autoimmune diseases; and compared with a traditional engineered immune cell, the engineered immune cell has significantly improved tumor killing activity.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 13, 2024
    Assignee: BIOHENG THERAPEUTICS LIMITED
    Inventors: Yun Xing, Zhonghui Yan, Ying Xiong, Rongrong Pu, Jiangtao Ren, Xiaohong He, Yanbin Wang, Lu Han
  • BCMA-TARGETING SINGLE-DOMAIN ANTIBODY AND USE THEREOF
    Publication number: 20240018251
    Abstract: Provided in the present invention are a BCMA-targeting single-domain antibody and an encoding nucleotide sequence thereof. Also provided in the present invention are a multispecific antibody, a chimeric antigen receptor, and an antibody conjugate containing the BCMA single domain antibody, and a pharmaceutical composition and kit containing said antibodies, chimeric antigen receptor and antibody conjugate, and the use thereof in the diagnosis/treatment/prevention of diseases associated with BCMA expression.
    Type: Application
    Filed: October 25, 2021
    Publication date: January 18, 2024
    Applicant: BIOHENG THERAPEUTICS LIMITED
    Inventors: Guokun LI, Rongrong PU, Jiangtao REN, Xiaohong He, Yanbin Wang, Lu HAN
  • ENGINEERED IMMUNE CELL AND USE THEREOF
    Publication number: 20230138756
    Abstract: An engineered immune cell, which expresses (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and/or XCL1; the engineered immune cell can be used for treating cancer, infection, or autoimmune diseases; and compared with a traditional engineered immune cell, the engineered immune cell has significantly improved tumor killing activity.
    Type: Application
    Filed: May 24, 2021
    Publication date: May 4, 2023
    Inventors: Yun XING, Zhonghui YAN, Ying XIONG, Rongrong PU, Jiangtao REN, Xiaohong HE, Yanbin WANG, Lu HAN